Advancing in the fight against Aids

We continue to be committed to research into HIV and Aids to help improve the knowledge, prevention and treatment for this illness.

  • WHY 

    HIV affects close to 34 million people all over the world. After more than 20 years, our projects lead the research field and their results are currently helping more than 3,000 patients.


    We promote the creation and financing of scientific activity at two research institutes to fight against Aids, with the aim of helping to develop a cure. Research is key to being able to advance our knowledge of HIV and find effective treatments for infected patients.

    IrsiCaixa, the IrsiCaixa Institute for Aids Research.

    In 1995, and in collaboration with the Catalan government's Department of Health, we helped to set up this Institute in order to enhance knowledge on HIV (by studying its structure, variability, mechanisms of infection and multiplication and response to drugs) , prevent Aids and study treatments for HIV infection and Aids with the ultimate aim of eradicating this epidemic.

    On 1 March 2004 we proved the high efficacy of a new drug (dolutegravir) against HIV which has now been approved in Australia, Canada, USA and Europe, and which is currently undergoing the procedures for approval and sale in Spain.

    HIVACAT, programme to research and develop a vaccine against Aids.

    Since 2007, HIVACAT has been working to develop and obtain vaccines against HIV, both preventative to avoid HIV infection and also therapeutic to prevent the disease from developing. The consortium that makes up HIVACAT represents the first important collaboration in this area between government, researchers and business.


    The centres promoted by the "la Caixa" Foundation have teams of top class researchers and benefit from the collaboration of renowned international research centres.


    The IrsiCaixa Institute for Aids Research is an international benchmark in the study of this epidemic. It's located within the Hospital Germans Trias i Pujol. And its scientific committee is made up of internationally renowned researchers.


    The HIVACAT programme is implemented via a public-private consortium unprecedented in Spain that positions our country internationally at the head of research carried out in this field. The consortium is made up of IrsiCaixa, Hospital Clínic de Barcelona, Laboratorios Esteve, the Catalan government and FBLC.